Implementing long-acting injectable cabotegravir and rilpivirine in Africa

Lancet Infect Dis. 2024 Oct;24(10):1060-1061. doi: 10.1016/S1473-3099(24)00296-2. Epub 2024 May 28.

Authors

Chloe Orkin¹, Kyle Ring²

Affiliations

¹ Centre of Immunobiology, Queen Mary University of London, London E1 2AT, UK; Barts Health NHS Trust, London, UK. Electronic address: [email protected].
² Centre of Immunobiology, Queen Mary University of London, London E1 2AT, UK; Barts Health NHS Trust, London, UK.

PMID: 38821072
DOI: 10.1016/S1473-3099(24)00296-2

No abstract available

MeSH terms

Africa
Anti-HIV Agents* / administration & dosage
Anti-HIV Agents* / therapeutic use
Delayed-Action Preparations
Diketopiperazines
HIV Infections* / drug therapy
Humans
Injections
Pyridones* / administration & dosage
Pyridones* / therapeutic use
Rilpivirine* / administration & dosage
Rilpivirine* / therapeutic use

Substances

cabotegravir
Rilpivirine
Pyridones
Anti-HIV Agents
Delayed-Action Preparations
Diketopiperazines